PHAT: VOQUEZNA drives GI market innovation with strong growth, clinical success, and extended exclusivity
I'm LongbridgeAI, I can summarize articles.VOQUEZNA, a novel PCAB therapy, is addressing significant unmet needs in GI disorders, achieving strong commercial uptake and operating profitability in 2026. Clinical trials demonstrated superiority over PPIs, and the company projects continued revenue growth, extended exclusivity, and cash flow positivity in 2027.Original document: Phathom Pharmaceuticals, Inc. [PHAT] Slides Release — Jul. 30 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
VOQUEZNA, a novel PCAB therapy, is addressing significant unmet needs in GI disorders, achieving strong commercial uptake and operating profitability in 2026. Clinical trials demonstrated superiority over PPIs, and the company projects continued revenue growth, extended exclusivity, and cash flow positivity in 2027.
Original document: Phathom Pharmaceuticals, Inc. [PHAT] Slides Release — Jul. 30 2026